Oramed Pharmaceuticals Inc. reports material events and financial information through SEC filings that document its oral drug delivery business, investment-related agreements, and capital actions. Recent 8-K disclosures cover operating and financial results, option and warrant-related arrangements, payments tied to strategic investments, cash dividends, and material definitive agreements involving company assets and subsidiaries.
The filings also document Oramed’s common stock registration on the Nasdaq Capital Market and Tel Aviv Stock Exchange, its shareholder rights agreement, board-authorized distributions, and other capital-structure and governance matters. These records connect the company’s clinical-stage POD technology platform and oral insulin program with formal disclosures on liquidity, securities, contractual rights, and corporate events.
Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay sold 20,000 common shares on October 1, 2026, at a weighted average price of $4.51 per share. The shares were sold in multiple transactions at prices ranging from $4.440 to $4.650. The sale was made under a Rule 10b5-1 trading plan adopted March 30, 2026. Following the sale, 861,076 shares were directly held.
Oramed Pharmaceuticals Inc. COO & CBO Joshua Hexter sold 30,000 common shares on October 1, 2026, at a weighted average price of $4.511 per share. The sales were made under a Rule 10b5-1 trading plan adopted March 30, 2026. He directly held 1,328,130 shares after the sale.
Oramed Pharmaceuticals Inc. (ORMP) officer Avi Gabay reported a proposed sale of 20,000 common shares, with an aggregate market value of $93,400 and an approximate sale date of October 1, 2026. The sale is pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026. The notice also lists 73,360 shares sold July 1, 2026, for $330,742.20 during the prior three months.
Oramed Pharmaceuticals Inc. officer Joshua Hexter reported a proposed sale of 30,000 common shares, with an aggregate market value of $140,100.00 and a sale date of October 1, 2026. The sale is pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. A separate securities table lists 108,000 and 27,000 common shares issued upon vesting of RSUs on May 1, 2023.
Oramed Pharmaceuticals Inc. President and CEO Nadav Kidron reported that the issuer canceled all of his outstanding stock options on September 24, 2026, in an option exchange program. He received a fully vested restricted stock award of 349,497 shares, valued at $4.75 per share—the closing price on September 22, 2026—and equal to the aggregate Black-Scholes value of the canceled options. The canceled options covered 196,500, 190,000, 49,000, 97,000, 150,000, and 107,000 shares, with exercise prices of $3.16, $4.80, $7.77, $8.14, $10.40, and $13.89, respectively. Separately, the issuer granted him 368,765 restricted shares under its Amended and Restated 2019 Stock Incentive Plan. A separate holding entry lists 126,000 common shares held indirectly by a wholly owned corporation.
ORAMED PHARMACEUTICALS INC. COO & CBO Joshua Hexter reported that on September 24, 2026, the company canceled all his outstanding stock options under an option exchange program. In exchange, he received a 75,455-share restricted stock award, fully vested upon grant and valued at $4.75 per share, equal to the canceled options’ aggregate Black-Scholes value. The company also granted him a separate 209,291-share restricted stock award; vesting is subject to continued service.
ORAMED Pharmaceuticals (ORMP) canceled all outstanding stock options held by Chief Scientific Officer and director Miriam Kidron on September 24, 2026, under an option exchange program. In exchange, she received a 208,125-share restricted stock award that fully vested upon grant, valued at $4.75 per share, the September 22, 2026 closing price; the award equaled the canceled options’ aggregate Black-Scholes value. She also received a separate 209,291-share award under the Amended and Restated 2019 Stock Incentive Plan: 40% vested on the grant date, with the remaining 60% vesting in eight substantially equal quarterly installments over 24 months, subject to continued service. Unvested shares are subject to forfeiture. No Rule 10b5-1 plan is reported.
ORAMED PHARMACEUTICALS INC. Chief Financial Officer Gabay Avraham acquired a restricted stock award of 209,291 shares on September 24, 2026, under the Amended and Restated 2019 Stock Incentive Plan. Forty percent vests on the grant date; the remaining 60% vests in eight substantially equal quarterly installments over the 24-month period following the grant, subject to continued service. Unvested shares are subject to forfeiture under the award agreement and Plan. His direct holdings following the award were 881,076 shares.
ORAMED PHARMACEUTICALS INC. (ORMP) held its 2026 Annual Meeting of Stockholders on September 15, 2026. Stockholders re‑elected all six directors standing for election. They also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved an amendment to the Amended and Restated 2019 Stock Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 3,000,000, to a total of 12,500,000 shares. On a non‑advisory basis, stockholders approved the compensation of named executive officers and selected a three‑year frequency for future say‑on‑pay votes. The board determined that say‑on‑pay votes will be held every three years. An adjournment proposal was rendered moot because all other proposals received sufficient support.
Aquamarine Financial (Cayman) Ltd reports beneficial ownership of 2,512,175 shares of Oramed Pharmaceuticals Inc. common stock, representing 6.04% of the class as of June 30, 2026. Aquamarine holds sole voting and sole dispositive power over all reported shares and no shared power.